Glycogen Synthase Kinase-3

Abnormalities and Therapeutic Potential in Fragile X Syndrome

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Recent advances in understanding the pathophysiological mechanisms contributing to fragile X syndrome (FXS) have increased optimism that drug interventions can provide significant therapeutic benefits. Based on evidence that glycogen synthase kinase-3 (GSK3) is abnormally active in brain regions in the Fmr1 knockout mouse, there is substantial evidence that inhibitors of GSK3 reverse many abnormalities in Fmr1 knockout mice. GSK3 inhibitors that have been tested include lithium, a drug approved for use in human patients, as well as several more selective inhibitors of GSK3. Lithium was first found to improve behaviors in the Drosophila model of FXS. In Fmr1 knockout mice, administration of lithium or other GSK3 inhibitors significantly improved heightened audiogenic seizure susceptibility, hyperactive locomotor behavior, passive avoidance learning, sociability behaviors, macroorchidism, neuronal spine morphology, protein synthesis, astrogliosis, neural plasticity measured electrophysiologically as long-term depression or long-term potentiation, adult hippocampal neurogenesis, novel object recognition, temporal ordering cognition, and spatial processing. A pilot clinical trial of lithium in patients with FXS also found improvements in several behaviors. Taken together, these findings indicate that lithium and other inhibitors of GSK3 are promising candidate therapeutic agents for treating FXS.

Original languageEnglish (US)
Title of host publicationFragile X Syndrome
Subtitle of host publicationFrom Genetics to Targeted Treatment
PublisherElsevier
Pages261-275
Number of pages15
ISBN (Electronic)9780128045077
ISBN (Print)9780128044612
DOIs
StatePublished - May 26 2017

Fingerprint

Glycogen Synthase Kinase 3
Fragile X Syndrome
Lithium
Knockout Mice
Therapeutics
Avoidance Learning
Neuronal Plasticity
Long-Term Potentiation
Neurogenesis
Pharmaceutical Preparations
Cognition
Drosophila
Seizures
Spine
Clinical Trials
Depression
Brain
Proteins

Keywords

  • Fragile X syndrome
  • Glycogen synthase kinase-3
  • Lithium
  • Long-term depression
  • Novel object recognition

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Glycogen Synthase Kinase-3 : Abnormalities and Therapeutic Potential in Fragile X Syndrome. / Jope, Richard S.

Fragile X Syndrome: From Genetics to Targeted Treatment. Elsevier, 2017. p. 261-275.

Research output: Chapter in Book/Report/Conference proceedingChapter

Jope, Richard S. / Glycogen Synthase Kinase-3 : Abnormalities and Therapeutic Potential in Fragile X Syndrome. Fragile X Syndrome: From Genetics to Targeted Treatment. Elsevier, 2017. pp. 261-275
@inbook{6fa8814b80e641b49f28dcb468f1e239,
title = "Glycogen Synthase Kinase-3: Abnormalities and Therapeutic Potential in Fragile X Syndrome",
abstract = "Recent advances in understanding the pathophysiological mechanisms contributing to fragile X syndrome (FXS) have increased optimism that drug interventions can provide significant therapeutic benefits. Based on evidence that glycogen synthase kinase-3 (GSK3) is abnormally active in brain regions in the Fmr1 knockout mouse, there is substantial evidence that inhibitors of GSK3 reverse many abnormalities in Fmr1 knockout mice. GSK3 inhibitors that have been tested include lithium, a drug approved for use in human patients, as well as several more selective inhibitors of GSK3. Lithium was first found to improve behaviors in the Drosophila model of FXS. In Fmr1 knockout mice, administration of lithium or other GSK3 inhibitors significantly improved heightened audiogenic seizure susceptibility, hyperactive locomotor behavior, passive avoidance learning, sociability behaviors, macroorchidism, neuronal spine morphology, protein synthesis, astrogliosis, neural plasticity measured electrophysiologically as long-term depression or long-term potentiation, adult hippocampal neurogenesis, novel object recognition, temporal ordering cognition, and spatial processing. A pilot clinical trial of lithium in patients with FXS also found improvements in several behaviors. Taken together, these findings indicate that lithium and other inhibitors of GSK3 are promising candidate therapeutic agents for treating FXS.",
keywords = "Fragile X syndrome, Glycogen synthase kinase-3, Lithium, Long-term depression, Novel object recognition",
author = "Jope, {Richard S}",
year = "2017",
month = "5",
day = "26",
doi = "10.1016/B978-0-12-804461-2.00013-5",
language = "English (US)",
isbn = "9780128044612",
pages = "261--275",
booktitle = "Fragile X Syndrome",
publisher = "Elsevier",
address = "Netherlands",

}

TY - CHAP

T1 - Glycogen Synthase Kinase-3

T2 - Abnormalities and Therapeutic Potential in Fragile X Syndrome

AU - Jope, Richard S

PY - 2017/5/26

Y1 - 2017/5/26

N2 - Recent advances in understanding the pathophysiological mechanisms contributing to fragile X syndrome (FXS) have increased optimism that drug interventions can provide significant therapeutic benefits. Based on evidence that glycogen synthase kinase-3 (GSK3) is abnormally active in brain regions in the Fmr1 knockout mouse, there is substantial evidence that inhibitors of GSK3 reverse many abnormalities in Fmr1 knockout mice. GSK3 inhibitors that have been tested include lithium, a drug approved for use in human patients, as well as several more selective inhibitors of GSK3. Lithium was first found to improve behaviors in the Drosophila model of FXS. In Fmr1 knockout mice, administration of lithium or other GSK3 inhibitors significantly improved heightened audiogenic seizure susceptibility, hyperactive locomotor behavior, passive avoidance learning, sociability behaviors, macroorchidism, neuronal spine morphology, protein synthesis, astrogliosis, neural plasticity measured electrophysiologically as long-term depression or long-term potentiation, adult hippocampal neurogenesis, novel object recognition, temporal ordering cognition, and spatial processing. A pilot clinical trial of lithium in patients with FXS also found improvements in several behaviors. Taken together, these findings indicate that lithium and other inhibitors of GSK3 are promising candidate therapeutic agents for treating FXS.

AB - Recent advances in understanding the pathophysiological mechanisms contributing to fragile X syndrome (FXS) have increased optimism that drug interventions can provide significant therapeutic benefits. Based on evidence that glycogen synthase kinase-3 (GSK3) is abnormally active in brain regions in the Fmr1 knockout mouse, there is substantial evidence that inhibitors of GSK3 reverse many abnormalities in Fmr1 knockout mice. GSK3 inhibitors that have been tested include lithium, a drug approved for use in human patients, as well as several more selective inhibitors of GSK3. Lithium was first found to improve behaviors in the Drosophila model of FXS. In Fmr1 knockout mice, administration of lithium or other GSK3 inhibitors significantly improved heightened audiogenic seizure susceptibility, hyperactive locomotor behavior, passive avoidance learning, sociability behaviors, macroorchidism, neuronal spine morphology, protein synthesis, astrogliosis, neural plasticity measured electrophysiologically as long-term depression or long-term potentiation, adult hippocampal neurogenesis, novel object recognition, temporal ordering cognition, and spatial processing. A pilot clinical trial of lithium in patients with FXS also found improvements in several behaviors. Taken together, these findings indicate that lithium and other inhibitors of GSK3 are promising candidate therapeutic agents for treating FXS.

KW - Fragile X syndrome

KW - Glycogen synthase kinase-3

KW - Lithium

KW - Long-term depression

KW - Novel object recognition

UR - http://www.scopus.com/inward/record.url?scp=85054376156&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054376156&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-804461-2.00013-5

DO - 10.1016/B978-0-12-804461-2.00013-5

M3 - Chapter

SN - 9780128044612

SP - 261

EP - 275

BT - Fragile X Syndrome

PB - Elsevier

ER -